Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 3/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | FPR3 | P25089 | 1/20 | 0.30 |
| ▸ | FPR2 | P25090 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16589500 | 0.81 | HDAC6 (0.38) | CTSKHDAC6CA14HDAC1HDAC2 | |
| SCHEMBL10260946 | 0.80 | HDAC6 (0.40) | PDK2CTSKHDAC6CA14HDAC1 | |
| SCHEMBL1714516 | 0.79 | PDK2 (0.40) | PDK2CTSKHDAC6CA14HDAC1 | |
| SCHEMBL17407114 | 0.79 | PDK2 (0.40) | PDK2CTSKHDAC6CA14HDAC1 | |
| SCHEMBL22276510 | 0.79 | PDK2 (0.40) | PDK2CTSKHDAC6CA14HDAC1 | |
| SCHEMBL22276649 | 0.79 | PDK2 (0.40) | PDK2CTSKHDAC6CA14HDAC1 | |
| SCHEMBL16197654 | 0.79 | PDK2 (0.36) | PDK2CTSKHDAC6CA14HDAC1 | |
| SCHEMBL22782589 | 0.78 | PDK2 (0.36) | PDK2CTSKHDAC6CA14HDAC1 | |
| SCHEMBL23918634 | 0.78 | PDK2 (0.39) | PDK2CTSKHDAC6CA14HDAC1 | |
| SCHEMBL1040957 | 0.78 | PDK2 (0.39) | PDK2CTSKHDAC6CA14HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450306-B2 | Bradykinin B1-receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-28 | — | — | US | disclosed |
| US-8252785-B2 | Aryl sulfonamides as bradykinin-B1-receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-28 | — | — | US | disclosed |
| US-20110294775-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110021488-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021488-A1 | New Compounds | ABCG2, ADORA2B, ADORA3 | PDK2 878/4885CTSK 3590/4885HDAC6 1721/4885 |
| US-20110294775-A1 | NOVEL COMPOUNDS | TRPV1, OPRL1, TRPA1 | PDK2 2153/4885CTSK 491/4885HDAC6 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.